ERBB2 and triple-negative breast carcinoma: Interestingly, HER2 enriched and triple-negative breast cancers (TNBC) benefit more from low VEGF-A expression with HR values of 2.44 and 2.22, respectively, with significant p-values (p = 0.007 and p = 0.0013).